Takeda Pharmaceutical (NYSE:TAK) Hits New 52-Week High – Here’s Why

Takeda Pharmaceutical Co. (NYSE:TAK) hit a new 52-week high during mid-day trading on Tuesday . The company traded as high as $15.94 and last traded at $15.9050, with a volume of 469706 shares. The stock had previously closed at $15.69.

Analysts Set New Price Targets

Separately, Weiss Ratings reissued a “hold (c-)” rating on shares of Takeda Pharmaceutical in a research report on Monday, December 29th. One research analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold”.

Takeda Pharmaceutical Trading Up 1.3%

The company has a debt-to-equity ratio of 0.61, a quick ratio of 0.76 and a current ratio of 1.37. The stock has a market capitalization of $50.58 billion, a PE ratio of 198.81 and a beta of 0.03. The business’s 50-day moving average is $14.46 and its two-hundred day moving average is $14.64.

Takeda Pharmaceutical (NYSE:TAK) last issued its quarterly earnings results on Thursday, October 30th. The company reported $0.44 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of $0.44. Takeda Pharmaceutical had a net margin of 0.86% and a return on equity of 10.32%. The business had revenue of $7.30 billion for the quarter, compared to analyst estimates of $8.01 billion. Takeda Pharmaceutical has set its FY 2025 guidance at 3.250-3.250 EPS. As a group, equities research analysts anticipate that Takeda Pharmaceutical Co. will post 1.64 earnings per share for the current year.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in TAK. Capital Research Global Investors boosted its stake in shares of Takeda Pharmaceutical by 0.8% during the 3rd quarter. Capital Research Global Investors now owns 13,404,129 shares of the company’s stock worth $196,236,000 after acquiring an additional 108,556 shares in the last quarter. UBS Group AG grew its holdings in Takeda Pharmaceutical by 46.4% in the third quarter. UBS Group AG now owns 5,893,969 shares of the company’s stock valued at $86,288,000 after purchasing an additional 1,869,323 shares during the last quarter. Goldman Sachs Group Inc. increased its position in shares of Takeda Pharmaceutical by 15.0% in the first quarter. Goldman Sachs Group Inc. now owns 5,320,793 shares of the company’s stock valued at $79,120,000 after buying an additional 692,404 shares in the last quarter. Brandes Investment Partners LP boosted its position in shares of Takeda Pharmaceutical by 5.9% in the 2nd quarter. Brandes Investment Partners LP now owns 3,712,278 shares of the company’s stock worth $57,392,000 after buying an additional 208,136 shares in the last quarter. Finally, Arrowstreet Capital Limited Partnership increased its holdings in Takeda Pharmaceutical by 132.1% during the 3rd quarter. Arrowstreet Capital Limited Partnership now owns 2,828,778 shares of the company’s stock valued at $41,413,000 after acquiring an additional 1,610,088 shares in the last quarter. 9.17% of the stock is owned by hedge funds and other institutional investors.

About Takeda Pharmaceutical

Takeda Pharmaceutical Company Limited (NYSE: TAK) is a Tokyo-based, multinational biopharmaceutical company with roots dating back to 1781. The company researches, develops, manufactures and commercializes pharmaceutical and biopharmaceutical products for patients worldwide. Takeda is publicly listed and operates as a fully integrated R&D-driven healthcare company focused on delivering specialty medicines and therapies across a range of therapeutic areas.

Takeda’s main business activities encompass discovery and development of prescription medicines, clinical development and regulatory affairs, manufacturing of small molecules and biologics, and global commercial operations.